22项鼻窦结局测试中新型过敏特异性域的验证
本研究为前瞻性验证研究,在三级医院及社区诊所开发并评估22项鼻窦结局测试(SNOT-22)中新型过敏特异性域的有效性,用于量化过敏性鼻炎(AR)合并慢性鼻窦炎的影响。因子分析显示所提过敏条目映射为单一域,内部一致性良好(域内Cronbach α=0.80,全SNOT α=0.91)。该域与MiniRQLQ(Spearman ρ=0.46,95%CI 0.30-0.59)和NOSE(0.36,95%CI 0.27-0.44)呈收敛效度,并能区分临床状态,重测信度良好(Cohen κ=0.8,95%CI 0.8-0.9),且对变化有反应性(均差-0.6,95%CI -0.8至-0.4)。
要点
- 新型过敏特异性域内部一致性良好(域内Cronbach α=0.80)。
- 域评分与MiniRQLQ(ρ=0.46)和NOSE(ρ=0.36)呈收敛效度。
- 域评分每增加1分,因过敏症状就诊的比值增加8.32(95%CI 5.43-12.75)。
核心结论
- 该新型域是测量过敏性鼻炎合并鼻窦炎的有效、高效工具。
研究设计与样本
- 前瞻性验证研究,在三级医院和社区诊所开展。
- 因子分析和内部一致性评估样本量n=1987。
- 收敛效度和区分效度评估样本量n=415。
主要发现
- 因子分析显示所提过敏条目映射为单一域。
- 内部一致性:域内Cronbach α=0.80,全SNOT α=0.91。
- 收敛效度:域评分与MiniRQLQ相关(Spearman ρ=0.46,95%CI 0.30-0.59),与NOSE相关(0.36,95%CI 0.27-0.44)。
- 区分效度:域评分每增加1分,因过敏相关症状就诊的比值增加8.32(95%CI 5.43-12.75),过敏试验阳性的比值增加1.52(95%CI 1.13-2.05)。
- 重测信度:Cohen κ=0.8(95%CI 0.8-0.9);反应性:均差-0.6(95%CI -0.8至-0.4)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To develop and assess the validity of a novel allergy-specific domain for the 22-item sino-nasal outcomes test (SNOT-22), to provide a new tool that efficiently quantifies the impact of allergic rhinitis (AR) concurrent with chronic rhinosinusitis. STUDY DESIGN: Prospective validation study. SETTING: Tertiary care hospital and community-based clinic. METHODS: Proposed items were developed based on clinician and patient input, and further assessed via factor analysis and for internal consistency (n = 1987). Items were then additionally assessed for convergent and discriminant validity (n = 415), applying data from concurrent completions of the Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE), Mini-Rhinoconjunctivitis Quality-of-Life Questionnaire (MiniRQLQ), and validated global health assessments. Assessments of intra-rater reliability, responsiveness to change, and qualitative input were also performed. RESULTS: Factor analysis demonstrated that proposed allergy items mapped to a single domain. Items were internally consistent (Cronbach α: 0.80 within domain, 0.91 within all SNOT). In assessments of convergent validity, domain scores were associated with MiniRQLQ (Spearman's ρ: 0.46, 95% confidence interval [CI]: 0.30-0.59) and NOSE scores (0.36, 95% CI: 0.27-0.44). The novel items also discriminated among clinical states: a 1-point increase in domain score was associated with an 8.32 (95% CI: 5.43-12.75) increase in the odds of prompting a visit for allergy-related symptoms and a 1.52 (95% CI: 1.13-2.05) increase in the odds of positive allergy testing. Intra-rater reliability was substantial (Cohen's κ: 0.8, 95% CI: 0.8-0.9), and responsiveness to change was demonstrated (mean difference: -0.6, 95% CI: -0.8 to -0.4). CONCLUSIONS: This novel domain is a valid, efficient measure of AR alongside rhinosinusitis.
引用
- Feng AY, Kim M, Prince AA, et al. Validation of a Novel Allergy-Specific Domain for the 22-Item Sino-Nasal Outcomes Test. Otolaryngol Head Neck Surg. 2023. PMID: 38091372. doi:10.1002/ohn.605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。